Farah Khorassani
Biography
Farah Khorassani, Pharm.D., BCPP, FAAPP is Health Sciences Clinical Professor in the Department of Clinical Pharmacy Practice at the University of California, Irvine, where she also serves as Clinical Pharmacist in Psychiatry at UC Irvine Health and Core Faculty for the Train-New-Trainers Fellowship at the UC Irvine School of Medicine. A Board Certified Psychiatric Pharmacist, Khorassani completed her Doctor of Pharmacy degree at Massachusetts College of Pharmacy and Health Sciences, followed by an ASHP-accredited PGY-1 Pharmacy Practice Residency at NewYork-Presbyterian Hospital and a PGY-2 Psychiatric Specialty Residency at University of North Carolina Hospitals and Clinics. Her clinical and scholarly work focuses on psychopharmacology, with particular emphasis on health disparities in psychiatric medication prescribing and the integration of mental health education into pharmacy curricula.
Khorassani has published over 20 peer-reviewed journal articles examining topics including treatment-resistant depression, antipsychotic-induced metabolic effects, pharmacogenomic testing in psychiatry, and racial disparities in psychotropic prescribing. Her research on racial disparities in mood stabilizer prescribing for bipolar disorder and short-acting intramuscular antipsychotics for agitation in schizophrenia has contributed to understanding inequities in psychiatric care. She has also authored peer-reviewed book chapters and developed institutional guidelines for clozapine use, long-acting injectable antipsychotics, and naltrexone administration at multiple hospital systems. Her work has been featured in national pharmacy publications and media outlets, and she serves as a reviewer for multiple pharmacy and psychiatry journals.
Khorassani serves in appointed leadership roles including Vice Chair of the Board of Pharmacy Specialties Psychiatric Pharmacy Specialty Council, Chair-elect of the American College of Clinical Pharmacy Central Nervous System Practice and Research Network, and Chair of the American Association of Psychiatric Pharmacists Abstracts Committee. She is a certified Mental Health First Aid Instructor and has delivered continuing education presentations at national conferences including the American Society of Clinical Psychopharmacology and American College of Clinical Pharmacy. At UC Irvine, she coordinates psychiatric pharmacy education for pharmacy students and residents, provides weekly teaching to psychiatry residents, and mentors students in scholarly research projects focused on psychopharmacology and mental health literacy.
Return to topEducation
- Pharm.D., Massachusetts College of Pharmacy and Health Sciences, 2011
- B.A. in Chemistry, University at Buffalo, State University of New York, 2008
Distinctions
- Fellow of the American Association of Psychiatric Pharmacists , 2026
- Board Certified Psychiatric Pharmacist (BCPP), Board of Pharmacy Specialties, 2014
Areas of Expertise
- Psychiatric Pharmacotherapy
- Clozapine Monitoring Protocols
- Long-Acting Injectable Antipsychotics
- Substance Use Disorder Management
- Pharmacogenomic Testing Applications
- Racial Disparities in Prescribing
- Antipsychotic-Induced Weight Gain
- Psychopharmacology
- Serious Mental Illness
Recent Publications
- Khorassani F., Espejo G., Lee K.C., “Obstetric Outcomes With Second-Generation Long-Acting Injectable Versus Oral Antipsychotics” (opens in new tab), Journal of Clinical Psychiatry, vol. 87, 2026.
- Khorassani F, Entsuah N, Sayer M, Ozaki A, “Racial disparities in mood stabilizer prescribing in mania in nonpsychotic, hospitalized patients with bipolar I disorder” (opens in new tab), Journal of Clinical Psychiatry, vol. 86, no. 1, pp. 24m15524, 2025.
- Espejo G, Khorassani F, “Clozapine Revisited: Updates to the Gold Standard”, Psychiatric News, 2025.
- Arms L, Khorassani F, Kim J, “Chapter 12: Psychotic Disorders”, Primary Care Psychiatry, 3rd ed, Wolters Kluwer, 2025.
- Park J, Espejo G, Khorassani F, “Mania or impulse control disorder? Recognizing dopamine agonist-induced behaviors”, ACCP Central Nervous System Practice and Research Network: Spring Newsletter, 2025.
- Lim G, Le T, Ngo A, Khorassani F, “Evaluation of the appropriateness of haloperidol decanoate dosing in inpatients with serious mental illness”, Ment Health Clin, vol. 15, no. 2, pp. 110, 2025.
- Khorassani F, Vu B, Espejo G, “Racial disparities in short-acting intramuscular antipsychotics for agitation in schizophrenia”, J Am Coll Clin Pharm, vol. 8, pp. 621-677, 2025.
- Khorassani F, Espejo G, “Evaluation of the impact of pharmacist-driven physician naloxone training on an inpatient psychiatric unit” (opens in new tab), Academic Psychiatry, vol. 48, pp. 1-5, 2024.
- Khorassani F, Jermain M, Cadiz C, “Pharmacogenomic testing to guide treatment of major depressive disorder: a systematic review” (opens in new tab), Current Treatment Options in Psychiatry, vol. 11, pp. 123-140, 2024.
- Khorassani F, Azevedo R, Farokhpay R, “Therapeutic drug monitoring vs. pharmacogenetic testing in the context of elevated olanzapine concentrations and prior clozapine intolerability: a case study” (opens in new tab), BMC Psychiatry, vol. 24, pp. 885-90, 2024.
- Khorassani F, “Clinical Pearl: Ethnicity-based considerations in clozapine prescribing”, ACCP Central Nervous System Practice and Research Network: Spring Newsletter, 2024.
- Khorassani F, “Vesicular Monoamine Transporters for Tardive Dyskinesia”, The Carlat Hospital Psychiatry Report (TCPR), vol. 1, no. 3, pp. 1-8, 2021.
- Khorassani F, “Battle of the bulge: antipsychotic-induced weight gain”, The Carlat Hospital Psychiatry Report (TCPR), vol. 1, no. 5, pp. 1-12, 2021.
- Khorassani F, Hassani B, Conry J, Espejo G, “Evaluation of anxiety in Doctor of Pharmacy students in their first through fourth professional years” (opens in new tab), Currents in Pharmacy Teaching and Learning, vol. 13, no. 6, pp. 628-34, 2021.
- Khorassani F, Talreja O, Luther K, “Valbenazine and deutetrabenazine: vesicular monoamine transporter 2 inhibitors for tardive dyskinesia” (opens in new tab), American Journal of Health System Pharmacy, vol. 77, no. 3, pp. 167-174, 2020.
- Khorassani F, Sousonis F, Lopez L, “Risperidone and paliperidone-induced hepatotoxicity: case report and review of literature” (opens in new tab), American Journal of Health System Pharmacy, vol. 77, no. 19, pp. 1578-84, 2020.
- Ng K, Khorassani F, “Options for managing treatment-resistant depression”, U S Pharmacist, vol. 44, pp. 38-45, 2019.
- Khorassani F, Saad M, “Intravenous olanzapine for the management of agitation: review of the literature” (opens in new tab), Annals of Pharmacotherapy, vol. 53, no. 8, pp. 853-59, 2019.
- Kennedy ML, Khorassani F, “Eating disorders: anorexia nervosa, bulimia nervosa, and binge eating disorders”, PharmacotherapyFirst: a multimedia learning resource, 2019.
Most Cited Publications
- Shirazian S, Grant CD, Aina O, Mattana J, Khorassani F, Ricardo A, “Depression in chronic kidney disease and end stage renal disease: similarities and differences in diagnosis, epidemiology, and management” (opens in new tab), Kidney International Reports, vol. 2, pp. 94-107, 2017.
- Khorassani F, Misher A, Garris S, “The past and present of anti-obesity agents: a focus on monoamine modulators” (opens in new tab), American Journal of Health System Pharmacy, vol. 72, pp. 697-706, 2015.
- Khorassani F, Hilas O, “Bapineuzumab: a novel investigational agent for Alzheimer's disease”, P and T, vol. 38, no. 2, pp. 1-3, 2013.
- Khorassani F, Talreja O, “Esketamine: a novel agent for treatment-resistant depression” (opens in new tab), American Journal of Health System Pharmacy, vol. 77, no. 17, pp. 1382-1388, 2020.
This profile was created with the help of AI.
Last updated on 7/2/2026.